Xiao, Qingyang
Koutsilieri, Stefania
Sismanoglou, Despoina-Christina
Lauschke, Volker M. http://orcid.org/0000-0002-1140-6204
Funding for this research was provided by:
Vetenskapsrådet (2016-01153, 2016-01154, 2019-01837)
Innovative Medicines Initiative (875510)
Karolinska Institute
Article History
Received: 31 January 2022
Accepted: 31 May 2022
First Online: 17 June 2022
Declarations
:
: V.M.L. declares no conflict of interest according to the ICMJE Uniform Requirements but discloses the following financial relationships: CEO and shareholder of HepaPredict AB; co-founder and chairman of the board PersoMedix AB; consultancy work for Enginzyme AB. The other authors declare no competing interests.
: The analyzed data is available for aggregate, deidentified analysis and, thus, IRB approval specific to this study was not required.
: Not applicable.